Le Lézard
Classified in: Science and technology
Subject: PDT

LIFARS Introduces Cyber Vaccine in the Battle Against Ransomware Attacks


NEW YORK, Dec. 6, 2019 /PRNewswire/ -- LIFARS, the global leader in cyber incident response, digital forensics, and security services announced the release of Cyber Vaccine, a new weapon against one of the most prolific organized crime phenomena of the 21st century ? ransomware attacks. Cyber Vaccine was crafted specifically for the Dridex malware strain, commonly used by the large-scale ransomware campaigns known as BitPaymer and DoppelPaymer.

(PRNewsfoto/LIFARS)

These campaigns have collected millions of dollars in recent years, crippling large, mid, and even small sized companies across the globe. As businesses try to adjust to this new threat and address the fears of clients and stakeholders, one thing remains clear ? the threat is real. There is no quick, easy or cheap way out once your organization is hit... or is there? Queue Cyber Vaccine.

A major leverage for receiving a ransom payment is the victim's alternative arduous and costly undertaking of rebuilding an infected business infrastructure.  During clean up and rebuild, customers and stakeholders grow agitated because of the business impact caused by the work-stoppage.  Where normally the recovery takes days, weeks, or months, recovery with Cyber Vaccine could potentially happen overnight. And, it just requires one IT member who knows how to administer it.  "Something we've seen over and over during incident response cases is a detrimentally lean IT team. Understaffing makes day-to-day cyber hygiene nearly impossible, let alone a full network rebuild after a ransomware attack," explains LIFARS IR Project Manager.

That common scenario makes Cyber Vaccine even more critical to recovery efforts.  It is fast-acting and thorough, allowing even understaffed IT teams to recover without a full wipe and rebuild of all the infected systems. "It takes a virus to kill a virus," explains LIFARS CEO Ondrej Krehel, "Cyber Vaccine is the new offensive measure in malware eradication."

When asked why LIFARS is offering Cyber Vaccine as open source, the malware researcher who created it, dubbed mwlac, explains "It is important that we all work together to fight these criminal groups. The less threat intelligence we share, the worse off we all are and the more money the criminals make."

The technical write-up for Cyber Vaccine is available online at https://lifars.com/2019/11/analysis-of-dridex-bitpaymer-and-doppelpaymer-campaign/

Cyber Vaccine's open source code, created by LIFARS, is available on GitHub: https://github.com/Lifars/Dridex-Vaccine

For more info: [email protected] or +1 (212) 222-7061 and www.LIFARS.com

SOURCE LIFARS


These press releases may also interest you

at 00:05
PitchBook, the premier data provider for the private and public equity markets today released The Global VC Ecosystem Dashboard that ranks the world's top startup cities. This dashboard leverages PitchBook data and PitchBook Institutional Research...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
DHGATE Group has won the "Best B2B Cross-Border E-Commerce Marketplace Company China 2024" award at the Global Business & Finance Magazine Awards. The award recognizes leading enterprises with innovation and leadership from various industries, and...

18 avr 2024
For the fourth straight quarter, Fluency has been named #1 by G2 in several key customer-centric...

18 avr 2024
Vipshop Holdings Limited , a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that the Company has filed its annual report on Form 20-F that includes its audited financial statements for three years...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....



News published on and distributed by: